Behind the Insights: Ep 06 FDA Draft Guidance on Post-Approval Data for Cell & Gene Therapies
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Behind the Insights: Ep 06 FDA Draft Guidance on Post-Approval Data for Cell & Gene Therapies
-
Narrado por:
-
De:
In this episode of Behind the Insights, Rich Gliklich, MD, Founder and CEO and Michelle Leavy, MPH, Senior Director, Registries at OM1 unpack the FDA's new draft guidance on Postapproval Methods to Capture Safety and Efficacy Data for Cell and Gene Therapy Products. They'll discuss practical considerations sponsors need to know and provide expert insights on compliant, cost-effective postapproval data strategies.
0:00 Intro
0:33 What is the new FDA draft guidance about and why is it important?
2:45 Main limitations of traditional real-world data sources?
4:09 How do registries fill gaps?
6:13 Decentralized data collection in practice
8:22 What do sponsors need to keep in mind?
9:22 Final thoughts
📩 Stay updated on future episodes: https://go.om1.com/l/1071043/2025-02-10/bk8151
🎯 Follow us! LinkedIn: https://www.linkedin.com/company/om1-inc./
Facebook: https://www.facebook.com/profile.php?id=61573205886660
X: https://x.com/Om1Inc
🌐 Visit our website: https://www.om1.com/
#fda #clinicalregistries #clinicalresearch #realworlddata #rwd #realworldevidence #rwe #pharma